Skip to content
10-Q

Quarterly Report

VitaNova Life Sciences Corporation VNOV

0001683168-25-001661

← back to feed
Filed
Mar 17, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2025 · Feb 26, 2025 25.01M sh
Current Liabilities Q3 2025 · Jan 31, 2025 $212.79K
Current Liabilities Q3 2025 · Apr 30, 2024 $136.92K
Total Liabilities Q3 2025 · Jan 31, 2025 $212.79K
Total Liabilities Q3 2025 · Apr 30, 2024 $136.92K
Current Assets Q3 2025 · Jan 31, 2025 $1.32M
Current Assets Q3 2025 · Apr 30, 2024 $1.19M
Total Assets Q3 2025 · Jan 31, 2025 $1.32M
Total Assets Q3 2025 · Apr 30, 2024 $1.19M
Shares Diluted Q3 2025 · Jan 31, 2024 6.08M sh
Shares Diluted Q3 2025 · Jan 31, 2024 25.01M sh
Operating Cash Flow Q3 2025 · Jan 31, 2024 −$184.7K
Stockholders Equity Q3 2025 · Jan 31, 2024 $870.78K
Stockholders Equity Q3 2025 · Oct 31, 2023 −$92.22K
Stockholders Equity Q3 2025 · Jul 31, 2023 −$83.46K
Stockholders Equity Q3 2025 · Apr 30, 2023 −$59.22K
Eps Diluted Q3 2025 · Jan 31, 2024 $0.00
Eps Diluted Q3 2025 · Jan 31, 2024 $0.00
Eps Basic Q3 2025 · Jan 31, 2024 $0.00
Eps Basic Q3 2025 · Jan 31, 2024 $0.00
Sga Expense Q3 2025 · Jan 31, 2024 $20.15K
Sga Expense Q3 2025 · Jan 31, 2024 $53.15K
Net Income Q3 2025 · Jan 31, 2024 $5.95K
Net Income Q3 2025 · Jan 31, 2024 −$27.05K
Net Income Q3 2025 · Oct 31, 2023 −$8.76K
Net Income Q3 2025 · Jul 31, 2023 −$24.25K
Operating Income Q3 2025 · Jan 31, 2024 $5.95K
Operating Income Q3 2025 · Jan 31, 2024 −$27.05K
Gross Profit Q3 2025 · Jan 31, 2024 $26.1K
Gross Profit Q3 2025 · Jan 31, 2024 $26.1K
Cost Of Revenue Q3 2025 · Jan 31, 2024 $0
Cost Of Revenue Q3 2025 · Jan 31, 2024 $0
Revenue Q3 2025 · Jan 31, 2024 $26.1K
Revenue Q3 2025 · Jan 31, 2024 $26.1K